Drug-Coated Balloons Market Size By Type, By Distribution Ch...| MENAFN.COM

Friday, 01 July 2022 01:11 GMT

Drug-Coated Balloons Market Size By Type, By Distribution Channel, And Forecast Till 2022-2031


(MENAFN- Comserve)

Shibuya-ku, Tokyo, Japan, Japan, Jun 23, 2022, 04:13 /Comserve / -- Drug-Coated Balloons Market Revenue, Regional & Country Share, Key Factors, Trends & Analysis, To 2022-2031

The  global drug-coated balloons market is expected to reach revenues of more than $1 billion by 2024, growing at a CAGR of around 17% during 2022-2031.

The global drug-coated balloons market is driven by the spreading awareness, education, and support for several CVDs. The DCBs market is one of the fastest growing segments in cardiovascular devices segment in the healthcare industry. The market research report provides in-depth market analysis and segmental analysis of the global drug-coated balloons market by indication, end-users, and geography.The report considers the present scenario of the global drug-coated balloons market and its market dynamics for the period 2019−2024. It covers the market by geography (North America, Europe, APAC, and ROW); by end-users (hospitals, cardiac catheterization labs, and ambulatory surgical centers); by indication types (DCBs for peripheral artery diseases, DCBs for coronary artery diseases, and DCBs for other indications). The study elaborates the present market scenario and discusses the futuristic demand for DCBs in the market. It also covers a detailed overview of several market growth enablers, restraints, and trends. The study includes both the demand and supply sides of the market. It also profiles and analyzes the leading companies and several other prominent companies operating in the market.

Download PDF Sample For More Information : 

Drug-Coated Balloons Market – Dynamics

There has been an increasing usage of Drug-coated balloons over the standard PTA Balloons for treating peripheral and coronary arterial diseases. The rapid growth and need for significant improvement in MI procedures and MI surgical techniques have led to this technical improvement in the balloon catheter segment. This significant development and launch of several drug-coated balloons have enhanced the safety, effectiveness and clinical outcomes of angioplasty procedures.A lot of vendors have a rich pipeline of devices for arterial, AVF, and AVG indications. Significant players in the market have their own in-house R&D activities to develop and commercialize DCB's. They have promising investigational DCBs under development and most of the small players are also actively involved in the development of novel and advanced drug-coated balloon devices. The vendors are conducting clinical trials to ensure the safety and for seeking regulatory approval from the USFDA in the coming years previously drug-coated balloons were only used for treating SFA in patients with PAD. Due to improvements in technological innovations, and increased clinical trials the application of this is expanded and used to treat other endovascular diseases. These days PAD patients with BTK artery lesions, small vessel disease, complex CAD, AVG, and AVF are also treated with advanced drug-coated balloon's. In recent years, the regulatory bodies gave expanded indication approvals for the existing commercial drug-coated balloons.

Request Sample For More Insights : 

Drug-Coated Balloons Market – Segmentation

This market research report includes a detailed segmentation of the market by indication, end-users, and geography.The global drug-coated balloons market by indication is classified into DCB for peripheral artery disease, DCB for coronary artery disease, and DCB for other indications. DCB for peripheral artery disease segment dominated the majority of total market share in 2018, growing at a CAGR of over more than 16% during the forecast period. The increasing advancements in endovascular therapy are propelling the growth of this segment in the global market. This procedure has offered a significant breakthrough and completely changed the treatment landscape of PAD, especially femoropopliteal artery disease.The growing demand for treatment options of complex coronary artery lesions, such as small-vessel disease and long diffuse CAD is fueling the growth of this segment in the global market. The development of drug-coated balloons technology is a viable alternative treatment option for the inhibition of coronary restenosis and subsequent revascularization in patients with CAD, thereby, fueling the demand in the global DCB market. Many vascular surgeons believe that these procedures are superior and cost-effective than treating CAD with DES in the long-term in the market.

The end-user segment in the global drug-coated balloons market is categorized into hospitals, cardiac catheterization labs, and ASCs. ASCs is the fastest growing end-user segment in the global market, at a CAGR of over 19% during the forecast period. The growing shift from open cardiovascular surgical techniques toward MI and percutaneous-based procedures especially across developed countries is contributing to the growth of the ASC segment in the global market. The technological advancements in interventional procedures, increasing demand for less invasive surgeries, and high growth in the development of out-patient services are some of the factors attributing to the rising demand for ASCs in the global market.The growing demand for highly advanced and innovative catheter-based cardiovascular and endovascular procedures will boost the adoption of drug-coated balloons across hospitals. Hospitals in developed countries such as the US, Germany, France, and Japan are adopting these procedures. These angioplasty procedures for treating a broad range of high-risk and complicated vascular diseases are gaining immense popularity among renowned hospitals, resulting in higher revenues in the global DCB market.

Market Segmentation by Indications
• DCB for Peripheral Artery Disease
• DCB for Coronary Artery Disease
• DCB for Other Indications

Market Segmentation by End-users
• Hospitals
• Cardiac Catheterization Labs
• ASCs

Drug-Coated Balloons Market – Geography

The global drug-coated balloons market by geography is segmented into North America, Europe, APAC, and ROW. North America occupied more than half of the total market share in 2018, growing at a CAGR of more than 18% during the forecast period. The growing prevalence of various cardiovascular risk factors, such as high BP, smoking, lack of physical activity, obesity, and diabetes are the main factors boosting the adoption of these procedures in the North American market. The availability of advanced healthcare infrastructure, constant technological innovations, and growing acceptance for advanced MI endovascular devices will create lucrative opportunities for leading vendors operating in the North American market.The growing demand for MI endovascular procedures, changes in lifestyle patterns of people, rising geriatric population, and increasing prevalence of vascular diseases are some of the factors attributing to the growth of the European region in the global market. The development of sophisticated and established healthcare infrastructure and advanced services across Western Europe will contribute to the development of the European region in the global DCB market.

Market Segmentation by Geography
• North America
o US
o Canada
• Europe
o Germany
o France
• APAC
o Japan
o China
• ROW
o Israel
o Brazil

Key Vendor Analysis

The global drug-coated balloons market is highly dynamic due to the presence of international, regional, and local players. The top companies are focusing on wide geographical reach, diversified product portfolio, and a strong focus on innovation and research activities to attract a maximum of consumers in the global market. The emerging companies to expand their presence, enhance product portfolio, and improve expertise to sustain the competition in the market. The increase in M&A activities will drive consolidation in the global drug-coated balloons market.

The major vendors in the global market are:
• Medtronic
• BD
• B. Braun Melsungen
• Koninklijke Philips

Other prominent vendors include Boston Scientific, Opto Circuits (India), Acotec Scientific, AR Baltic Medical, Acrostak, Biosensors International Group, Cardionovum, Endocor, iVascular SLU, Minvasys, QT Vascular, BioMed ,SurModics, Concept Medical, Hexacath Sverige, RD Global-Invamed, MedAlliance, Terumo, and Wellinq.

Key market insights include
1. The analysis of global drug-coated balloons market provides market size and growth rate for the forecast period 2018-2024.
2. It offers comprehensive insights into current industry trends, trend forecast, and growth drivers about the global drug-coated balloons market.
3. The report provides the latest analysis of market share, growth drivers, challenges, and investment opportunities.
4. It offers a complete overview of market segments and the regional outlook of global drug-coated balloons market.
5. The report offers a detailed overview of the vendor landscape, competitive analysis, and key market strategies to gain competitive advantage.

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.


MENAFN23062022004694010674ID1104419842


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.